Rituxan - (10mg/mL; Vial)

Generic Name	Rituximab	Innovator	Genentech, Inc.
Dosage	10mg/mL; Vial	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Rituximab is used to treat rheumatoid arthritis and can decrease joint pain and swelling.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******			*******	****	*** ** ******
********* (****)			*******	******** ** *******	******** ** *** *, ****
******			*******/ *** ** ** ** '*** ******	******** ** ********	*** ****** *** ****

Chronology Of Events